SCHEMBL10293279

SCHEMBL10293279

CCOC(=O)N1CCN(C(=O)c2cc3cc(S(=O)(=O)N4CCC(C)CC4)ccc3[nH]2)CC1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.63
MEN1 O00255 5/20 0.63
GAA P10253 2/20 0.58
LMNA P02545 2/20 0.55
HTT P42858 2/20 0.55
RAB9A P51151 2/20 0.53
POLB P06746 2/20 0.53
NPC1 O15118 1/20 0.53
ATM Q13315 1/20 0.52
HCRTR1 O43613 1/20 0.51
KDM4E B2RXH2 2/20 0.50
MAPT P10636 1/20 0.50
CYP2C9 P11712 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
AKR1C3 P42330 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10293119 0.90 KMT2A (0.62) KMT2AMEN1GAALMNAHTT
SCHEMBL10293190 0.89 KMT2A (0.67) KMT2AMEN1LMNAHTTRAB9A
SCHEMBL8277436 0.89 KMT2A (0.63) KMT2AMEN1LMNAHTTPOLB
SCHEMBL8275565 0.87 HRH4 (0.58) KMT2AMEN1POLBHCRTR1HSD17B10
SCHEMBL10293208 0.87 KMT2A (0.60) KMT2AMEN1LMNAHTTRAB9A
SCHEMBL10293172 0.86 KMT2A (0.59) KMT2AMEN1LMNAHTTRAB9A
SCHEMBL8277168 0.86 KMT2A (0.59) KMT2AMEN1LMNAHTTRAB9A
SCHEMBL10293202 0.84 KMT2A (0.56) KMT2AMEN1RAB9APOLBNPC1
SCHEMBL10293104 0.83 KMT2A (0.58) KMT2AMEN1LMNAHTTPOLB
SCHEMBL8277465 0.83 GAA (0.63) KMT2AMEN1GAALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C KMT2A 3808/4885MEN1 3121/4885GAA 3479/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C KMT2A 3808/4885MEN1 3121/4885GAA 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.